bluebird bio, Inc. (BLUE) dropped -0.71% or -0.53 points to trade at $73.97 per share. As per the latest trading data available, the net money flow stood at $0.38 million as the shares received $0.97 million in upticks and gave away $0.59 million in downticks. The final up/down ratio was at 1.64. On a weekly basis, the stock has seen a change of 4.04%.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of bluebird bio, Inc. rose by 11.5% in the last five trading days and 22.53% for the last 4 weeks. bluebird bio, Inc. is up 58.32% in the last 3-month period. Year-to-Date the stock performance stands at 22.53%. bluebird bio, Inc. (NASDAQ:BLUE) rose 1.48% or 1.1 points on Wednesday and made its way into the gainers of the day. After trading began at $74.65 the stock was seen hitting $76.3 as a peak level and $73.15 as the lowest level. The stock ended up at $75.6. The daily volume was measured at 784,230 shares. The 52-week high of the share price is $79.7 and the 52-week low is $35.37. The company has a market cap of $2,820 million.
Company has reported several Insider transactions to the SEC, on Jan 31, 2017, James Mandell (director) sold 5,000 shares at 70.10 per share price.On Jan 31, 2017, Daniel Lynch (director) sold 1,000 shares at 70.09 per share price.On Jan 31, 2017, David Davidson (Chief Medical Officer) sold 6,000 shares at 68.85 per share price.
bluebird bio Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $-2.07 EPS for the quarter, missing the analyst consensus estimate by $ -0.48. Analyst had a consensus of $-1.59. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $1.82 million. The companys revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.18 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Maxim Group on Dec 1, 2016 to Buy, Raises Price Target to $ 87 from a previous price target of $57 .
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.